News

Video

Collecting Real-World Data from Patients With Myelofibrosis Is Essential

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

In an interview with Pharmacy Times, Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute, spoke about the importance of real-world data in patients with myelofibrosis. Komrokji presented at the 62nd American Society of Hematology Annual Meeting and Exposition on ‘To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study.’

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue